Case No. | Age | CV risk | Radiotherapy | Baseline LVEF (%) | Post Chemothx LVEF (%) | Trastuzumab Duration |
---|---|---|---|---|---|---|
1 | 33 | None | Yes | 55 | 52 | 4 months |
2 | 41 | HTN | Yes | 60 | 58 | 5 months |
3 | 27 | None | Yes | 54 | 56 | 4 months |
4 | 39 | None | Yes | 65 | 62 | 3 months |
5 | 44 | Lipids | Yes | 58 | 55 | 4 months |
6 | 38 | None | Yes | 56 | 52 | 5 months |
7 | 56 | HTN | Yes | 60 | 62 | 3 months |
8 | 45 | HTN | Yes | 54 | 55 | 4 months |
9 | 32 | None | Yes | 55 | 52 | 5 months |
10 | 40 | HTN | Yes | 60 | 58 | 4 months |